The World Health Organization recommends two other drugs, baricitinib and sotrovimab, for the treatment of Covid-19. Baricitinib, already used to treat rheumatoid arthritis, is strongly recommended for patients with severe disease or in a critical clinical situation, WHO explains. It is part of a class of drugs called Janus kinase (Jak) inhibitors, which suppress overstimulation of the immune system.
UK, Downing Street apologizes for lockdown parties the night before Philip’s funeral
by our correspondent Antonello Guerrera
The Geneva agency suggests that it be administered with corticosteroids. WHO has also conditionally recommended the monoclonal antibody sotrovimab for the treatment of mild or moderate Covid in patients at high risk of hospitalization, e.g. the elderly, immunocompromised, with underlying conditions such as diabetes, hypertension and obesity, and unvaccinated. .
Sotrovimab is indicated as an “alternative to casirivimab-imdevimab, a cocktail of monoclonal antibodies recommended by the WHO in September 2021 – recalls the Organization – Studies on the efficacy of monoclonal antibodies against” the variant “Omicron are underway, but the first studies laboratory – he specifies – show that sotrovimab maintains its activity “.
Covid, record number of cases in Germany: 92 thousand. But deaths are stable and intensive care is decreasing
by Roberto Brunelli
Today’s recommendations, which constitute the eighth update of the guidelines on Covid-19 therapies, are based on the analysis of 7 studies involving over 4 thousand patients with non-severe, severe and critical Covid. The guideline experts also looked at two other drugs for severe and critical Sars-CoV-2 disease: ruxolitinib and tofacitinib. Given their uncertain effects, however, WHO has made a conditional recommendation against their use.
.